Diabetes
Diabetes
Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work involving diabetes is below.
If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org
We’ve done an extensive amount of work on several dangerous diabetes drugs. These medications are: rosiglitazone (Avandia), pioglitazone (Actos) and troglitazone (Rezulin). Click on the names of these drugs to view the work we’ve done involving those medications.
More Information on Diabetes
- Testimony on Dapagliflozin, July 19, 2011
- Position Statement: FDA’s Decision Not to Take Rosiglitazone (Avandia) Off the Market Jeopardizes Public Health, September 23, 2010
- Testimony on Rosiglitazone (Avandia) Safety, July 14, 2010
- Letter Urging FDA to Halt Rosiglitazone (Avandia) Trial, May 11, 2010
- Testimony on Rosiglitazone (Avandia), April 28, 2010
- Letter to FDA Praising Food Safety Cautiousness, Attacking Drug Safety Recklessness, March 8, 2010
- Life-Threatening Liver Toxicity of Rosiglitazone (Avandia) Shown in New Public Citizen Research Published in Peer-Reviewed Medical Journal, July 22, 2009
- Petition to Ban Diabetes Drug Rosiglitazone (Avandia), October 30, 2008
- Testimony on Rosiglitazone (Avandia), July 30, 2007
- Letter Demonstrating that FDA Knew About Rosiglitazone (Avandia) Dangers, May 22, 2007
- Statement: New Evidence Confirms Public Citizen’s Warnings About the Risks of Popular Diabetes Drug Rosiglitazone (Avandia), May 21, 2007
- Letter Urging Rejection of Diabetes Drug Muraglitazar (Pargluva), November 21, 2005
- Testimony on Diabetes Drug Muraglitazar (Pargluva), September 9, 2005
- Testimony on Pramlintide (Symlin), July 26, 2001
- Letter in the Lancet on the Availability of Information on Thiazolidinediones, July 15, 2000
- Letter Requesting a Criminal Investigation of Warner Lambert/Parke Davis, March 14, 2000
- Petition Requesting Updated Labeling for Diabetes drugs Troglitazone (Rezulin), Rosiglitazone (Avandia) and Pioglitazone (Actos), March 7, 2000
- Letter in JAMA Responding to Article on the Safety of Withdrawn Drugs, December 2, 1999
- Testimony Advising the FDA to Withdraw Troglitazone (Rezulin), March 26, 1999
- Letter on Ad for Troglitazone (Rezulin), January 6, 1999
- Petition to Ban Troglitazone (Rezulin), July 27, 1998